

**The Australian Stock Exchange Limited
Companies Announcements Office
SYDNEY**

24th November 2009

**PROBIOMICS LIMITED SIGNS AN EXCLUSIVE GLOBAL DISTRIBUTION
AGREEMENT WITH CHR. HANSEN A/S OF DENMARK**

Probiomics Limited (“Probiomics” ASX Code:PCC) is pleased to advise that it has signed a major agreement with Chr. Hansen A/S of Horsholm, Denmark to manufacture and market its proprietary probiotic strain, Lactobacillus fermentum PCC® globally in dietary supplements, over the counter drugs, sports nutrition, slimming products, clinical nutrition, beverages, and dairy products.

Chr Hansen is a global leader in the development of natural ingredient solutions for food, pharmaceutical, nutritional and agricultural industries. It has 2,150 employees globally with presence in 30 countries and has distributors and agents around the world. During 2008/2009 Chr Hansen had sales of approx A\$ 900 million.

Probiomics Chairman Patrick Ford stated “Clearly this is a ground breaking deal for our Company. It means that our probiotic strain Lactobacillus fermentum PCC® will now be available in markets worldwide (including Australia). Without a major partner with global distribution like Chr. Hansen, this reach would not have been possible.” Mr Ford added “We are thrilled with this deal, and we believe that Probiomics will now be the beneficiary of substantial and increasing cash flows as a result”. The exclusive global distribution agreement is for a period of 10 years.

Speaking from Horsholm, Sune Schmolker, a Director at Chr.Hansen stated that “Signing the agreement is a result of more than 2 years of negotiations between Chr. Hansen and Probiomics and is the beginning of a fantastic relationship. We cannot wait to introduce the PCC® strain to our customers world-wide.”

This agreement is the culmination of clinical trials undertaken jointly by Probiomics and Chr. Hansen over 6 months in conjunction with Griffith University and the Australian Institute of Sport (AIS) on the immune system in a group of 99 athletes.

The double blinded, placebo-controlled study showed that PCC[®] was effective in reducing the severity and illness load of chest infection and medication use associated with respiratory tract infection (cold and flu). Furthermore, the researchers found that consuming PCC[®] moderated the negative effects of exercise stress on the immune system. The study is expected to be published at the beginning of 2010.

It was the second AIS study clearly supportive of PCC[®]

“The studies done with Australian Institute of Sports are very promising. The new AIS study definitively confirms the efficacy of PCC[®] and I think it is fair to say that this scientific confirmation is what tipped the scale and settled the agreement.” concludes Sune Schmolker from Chr. Hansen.

CONTACTS

Mr Ashok Jairath - Chief Financial Officer and Company Secretary
Tel: 02 9844 5422
Email ashok.jairath@probiomics.com.au

Sune Schmolker
Director, Commercial Development, Human Health, Chr. Hansen
Tel: +45 4574 7108
Email: dksus@chr-hansen.com

About Probiomics Limited

Probiomics has proprietary ownership of a unique probiotic strain – PCC[®]

PCC[®] has been clinically proved to have superior qualities – particularly in promoting systemic immune response.

Probiomics' commercial objective is to earn royalties from licensing PCC[®] to distribution companies selling products in global markets.

For further information, please go to www.probiomics.com.au

About Chr. Hansen

Chr. Hansen is a global biotechnology company that provides natural ingredients to the food, dairy, dietary supplement, pharmaceutical, and agricultural industries. Chr. Hansen is a leading supplier of food cultures, probiotics, enzymes, colors, and functional systems. Chr. Hansen offers superior documentation and innovation within probiotics for the food, agricultural, dietary supplement, infant formula and pharmaceutical industries. It has specialist staff who are able to provide knowledge, inspiration, support, and customized solutions to customers to create successful probiotic product portfolios.

For further information, please go to www.chr-hansen.com/probiotics